Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
CRH
CRH
|
$150M |
| 2 |
Kenvue
KVUE
|
$98.9M |
| 3 |
Sempra
SRE
|
$60.4M |
| 4 |
Copart
CPRT
|
$52.4M |
| 5 |
Textron
TXT
|
$50.7M |
Top Sells
| 1 |
Apple
AAPL
|
$1.12B |
| 2 |
Microsoft
MSFT
|
$890M |
| 3 |
Amazon
AMZN
|
$463M |
| 4 |
NVIDIA
NVDA
|
$425M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$316M |
Sector Composition
| 1 | Technology | 29.44% |
| 2 | Healthcare | 13.62% |
| 3 | Consumer Discretionary | 11.97% |
| 4 | Industrials | 9.14% |
| 5 | Communication Services | 8.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Gilead Sciences
GILD
$140B
| $301M | 0.24% | 4,012,200 -498,000 | -11% | -$37.3M |
|
77
Stryker
SYK
$150B
| $300M | 0.24% | 1,099,000 -133,400 | -11% | -$36.5M |
|
78
Vertex Pharmaceuticals
VRTX
$100B
| $288M | 0.23% | 828,400 -101,900 | -11% | -$35.4M |
|
79
CVS Health
CVS
$92.8B
| $288M | 0.23% | 4,123,760 -498,500 | -11% | -$34.8M |
|
80
Regeneron Pharmaceuticals
REGN
$61.5B
| $286M | 0.22% | 347,100 -41,200 | -11% | -$33.9M |
|
81
Analog Devices
ADI
$124B
| $282M | 0.22% | 1,612,875 -214,000 | -12% | -$37.5M |
|
82
Chubb
CB
$110B
| $277M | 0.22% | 1,332,291 -163,500 | -11% | -$34M |
|
83
Eaton
ETN
$136B
| $273M | 0.21% | 1,282,200 -155,300 | -11% | -$33.1M |
|
84
Cigna
CI
$80.3B
| $272M | 0.21% | 952,101 -120,700 | -11% | -$34.5M |
|
85
Lam Research
LRCX
$127B
| $271M | 0.21% | 432,200 -55,200 | -11% | -$34.6M |
|
86
Uber
UBER
$196B
| $269M | 0.21% | 5,858,700 -687,400 | -11% | -$31.6M |
|
87
Schlumberger
SLB
$55B
| $267M | 0.21% | 4,584,627 -544,600 | -11% | -$31.8M |
|
88
Progressive
PGR
$145B
| $262M | 0.21% | 1,882,500 -231,800 | -11% | -$32.3M |
|
89
Zoetis
ZTS
$69.3B
| $259M | 0.2% | 1,486,332 -184,200 | -11% | -$32M |
|
90
American Tower
AMT
$95.5B
| $247M | 0.19% | 1,499,100 -184,000 | -11% | -$30.3M |
|
91
Boston Scientific
BSX
$156B
| $244M | 0.19% | 4,624,300 -566,800 | -11% | -$29.9M |
|
92
T-Mobile US
TMUS
$284B
| $243M | 0.19% | 1,736,802 -439,200 | -20% | -$61.5M |
|
93
Canadian Natural Resources
CNQ
$65.9B
| $242M | 0.19% | 3,709,431 -457,300 | -11% | -$29.8M |
|
94
Altria Group
MO
$113B
| $241M | 0.19% | 5,741,600 -709,400 | -11% | -$29.8M |
|
95
Micron Technology
MU
$133B
| $240M | 0.19% | 3,523,100 -429,500 | -11% | -$29.2M |
|
96
EOG Resources
EOG
$68.2B
| $238M | 0.19% | 1,881,200 -241,600 | -11% | -$30.6M |
|
97
Enbridge
ENB
$105B
| $238M | 0.19% | 7,127,131 -492,400 | -6% | -$16.5M |
|
|
ATVI
98
DELISTED
Activision Blizzard Inc.
ATVI
| $237M | 0.19% | 2,528,600 -162,300 | -6% | -$15.2M |
|
99
Becton Dickinson
BDX
$55.3B
| $236M | 0.19% | 913,602 -111,800 | -11% | -$28.9M |
|
100
Canadian Pacific Kansas City
CP
$69.9B
| $234M | 0.18% | 3,118,993 -383,800 | -11% | -$28.8M |
|